导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -20.21% | 4409/4773 |
| 近一周 | -4.07% | 4992/5465 |
| 近一月 | -3.39% | 2462/5421 |
| 近一季 | -6.08% | 2278/5231 |
| 近半年 | -19.17% | 4335/4920 |
| 近一年 | -25.72% | 4107/4394 |
| 近两年 | 1.88% | 2867/2954 |
| 近三年 | -33.05% | 2228/2253 |
| 成立以来 | -46.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.06% 4340/4961 |
-11.98% 4372/5312 |
- - |
- - |
| 2025 | 1.55% 3224/4813 |
-5.86% 3321/3635 |
-1.47% 3170/4076 |
19.94% 2070/4524 |
-8.72% 3952/4813 |
| 2024 | -0.92% 2142/3463 |
-8.57% 2235/2808 |
-11.07% 2500/3014 |
32.47% 97/3129 |
-8.01% 2822/3463 |
| 2023 | -25.73% 1979/2656 |
-5.24% 2143/2280 |
-9.40% 2052/2385 |
0.68% 354/2515 |
-14.08% 2477/2655 |
| 2022 | -10.08% 196/2207 |
8.50% 17/1919 |
-9.24% 1905/2016 |
-8.03% 165/2113 |
-0.70% 1639/2208 |
| 2021 | -5.76% 982/1822 |
-1.96% 562/1255 |
-4.91% 1267/1330 |
0.68% 464/1466 |
0.41% 1120/1822 |
| 2020 | -7.36% 988/1250 |
-13.01% 915/1028 |
7.19% 847/1067 |
6.41% 841/1164 |
-6.63% 1145/1184 |
| 2019 | 26.43% 575/1092 |
31.18% 211/739 |
-8.79% 608/788 |
-3.91% 748/850 |
9.97% 175/918 |
| 2018 | -26.71% 393/834 |
- - |
-16.61% 557/631 |
-5.75% 378/660 |
-5.30% 32/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证房地产ETF发起联接C VS. 长安沪深300非周期A(740101) |